利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.013 秒)

    Homocysteine assay
    1.
    发明公开
    Homocysteine assay 失效
    Testverfahrenfür同型半胱氨酸

    公开(公告)号：EP0726322A1

    公开(公告)日：1996-08-14

    申请号：EP96200534.4

    申请日：1993-01-22

    申请人： AXIS BIOCHEMICALS AS

    发明人： Sundrehagen, Erling

    IPC分类号： C12Q1/34 ,  G01N33/53 ,  C12Q1/48 ,  C12Q1/66 ,  G01N33/58 ,  C07H15/14 ,  C07D307/32

    CPC分类号： C12Q1/48 ,  C07H15/14 ,  C07H15/26 ,  C07H19/16 ,  C12Q1/34 ,  G01N33/542 ,  G01N33/5735 ,  G01N33/68 ,  G01N33/6815

    摘要： There is provided a method for assaying homocysteine in a sample, e.g. blood, plasma or urine, which comprises the steps of contacting said sample with a homocysteine converting enzyme other than SAH-hydrolase and at least one substrate for said enzyme other than homocysteine, and without chromatographic separation assessing a non-labelled analyte selected from a homocysteine co-substrate and the homocysteine conversion products of the enzymic conversion of homocysteine by said enzyme.

    摘要翻译： 提供了在样品中测定同型半胱氨酸的方法，例如 血液，血浆或尿液，其包括使所述样品与除SAH-水解酶以外的同型半胱氨酸转化酶接触的步骤和除了同型半胱氨酸之外的所述酶的至少一种底物，并且不进行色谱分离，评估选自同型半胱氨酸 共底物和所述酶对同型半胱氨酸的酶转化的同型半胱氨酸转化产物。

    ANALYTE VARIANT ANALYSIS
    2.
    发明授权
    ANALYTE VARIANT ANALYSIS 失效
    分析分析物的变化。

    公开(公告)号：EP0535162B1

    公开(公告)日：1995-03-29

    申请号：EP91914885.8

    申请日：1991-06-20

    申请人： AXIS BIOCHEMICALS AS

    发明人： SUNDREHAGEN, Erling

    IPC分类号： G01N33/68 ,  G01N33/538 ,  G01N33/561

    CPC分类号： G01N33/6803 ,  G01N33/538 ,  G01N2333/79 ,  Y10S435/964 ,  Y10S435/975 ,  Y10S436/808

    摘要： The present invention provides a method of assessment of the concentration of a subset of variants in a population of proteinaceous analyte variants capable of separation by a fractionation system, wherein said population of variants are contacted with a population of labelled proteinaceous specific binding partners therefor to form labelled binding partner-analyte complexes therewith, which are then subjected to separation by the said fractionation system into one or more fractions containing said subset of analyte variants in complexed form and assessment of the amount of label in one or more fractions so obtained, the said population of specific binding partners having, prior to reaction, substantially uniform distribution or mobility in said fractionation system, compositions and test kits for use in such methods. The method of the invention is particularly suitable for the analysis of variants of the protein transferrin.

    GLYCOSYLATED HAEMOGLOBIN ASSAY
    3.
    发明授权
    GLYCOSYLATED HAEMOGLOBIN ASSAY 失效
    测定方法的糖化血红蛋白。

    公开(公告)号：EP0471774B1

    公开(公告)日：1995-01-25

    申请号：EP90908231.5

    申请日：1990-05-11

    申请人： AXIS BIOCHEMICALS AS

    发明人： SUNDREHAGEN, Erling

    IPC分类号： G01N33/72

    CPC分类号： G01N33/539 ,  G01N33/723 ,  Y10S436/815 ,  Y10S436/824 ,  Y10T436/25125 ,  Y10T436/25375

    摘要： This invention provides a method of assessing glycosylated haemoglobin in a sample, said method comprising the steps of: (a) optionally haemolysing the sample to liberate any cell bound haemoglobin; (b) contacting the said sample or haemoglobin recovered from said sample according to step (c) below with signal-forming molecules comprising a conjugate of one or more dihydroxyboryl residues or salts thereof, linked to a signal-forming label; (c) separating glycosylated and non-glycosylated haemoglobin and any molecules bound thereto, from the sample or from the reaction mixture of step (b) above; and (d) assessing the said signal forming molecules which have bound to the separated haemoglobin, and/or any non-haemoglobin bound signal-forming molecules; and an analytical test kit for use in accordance with the method of the invention. The new assay of the invention is particularly useful for the in vitro diagnosis and monitoring of diabetes mellitus.

    LABELLING AGENTS COMPRISING BORONIC ACID CONJUGATES
    5.
    发明授权
    LABELLING AGENTS COMPRISING BORONIC ACID CONJUGATES 失效
    硼酸偶联物含MARKER平台。

    公开(公告)号：EP0557357B1

    公开(公告)日：1995-03-22

    申请号：EP91920019.6

    申请日：1991-11-13

    申请人： AXIS BIOCHEMICALS AS

    发明人： FRANTZEN, Frank ,  SUNDREHAGEN, Erling

    IPC分类号： C07F5/02 ,  G01N33/52 ,  G01N33/72 ,  C09B19/00 ,  C09B21/00

    CPC分类号： G01N33/587 ,  C07F5/025 ,  G01N33/533

    摘要： Labelling agents comprising non-proteinaceous boronic acid conjugates having absorption maxima at not less than 600 nm, said label being provided by e.g. an azine, triphenylmethane, cyanine or phthalocyanine dye, are useful in the estimation and quantification of cisdiols such as glycosylated haemoglobin, by virtue of the substantially total absence of overlap with the absorption spectrum of haemoglobin. Oxazine and thiazine dyes exhibiting similar absorption characteristics and containing other activated moieties are similarly useful labelling agents, especially in the presence of haemoglobin.

    ASSAY FOR GLYCATED BLOOD PROTEINS
    6.
    发明授权
    ASSAY FOR GLYCATED BLOOD PROTEINS 失效
    糖化血液蛋白的测定。

    公开(公告)号：EP0557350B1

    公开(公告)日：1994-10-05

    申请号：EP91919886.1

    申请日：1991-11-13

    申请人： AXIS BIOCHEMICALS AS

    发明人： SUNDREHAGEN, Erling ,  FRANTZEN, Frank

    IPC分类号： G01N33/68 ,  G01N33/72

    CPC分类号： G01N33/6842 ,  G01N33/68 ,  G01N33/723 ,  Y10S436/815 ,  Y10S436/824 ,  Y10T436/25125 ,  Y10T436/25375

    摘要： There is provided a method of assessing a glycated blood protein in a sample, said method comprising the steps of a) optionally hemolysing said sample to liberate cell bound glycated protein; b) separating said glycated blood protein and the corresponding non-glycated blood protein from said sample; c) contacting said sample before or during separation of said glycated and non-glycated proteins therefrom or contacting said separated proteins with a first signal forming agent capable of binding to said glycated protein but not to the corresponding non-glycated protein; d) optionally, contacting said sample before or during separation of said glycated and non-glycated proteins therefrom or contacting said separated proteins with a second signal forming agent capable of binding to said glycated protein and to said corresponding non-glycated protein; and e) assessing the signal forming agents which have bound to said separated proteins and/or which have not bound to said glycated protein or said corresponding non-glycated protein; with the proviso that where said glycated protein comprises glycated hemoglobin said first signal forming agent is a chromophore labelled boronic acid or salt thereof having an absorption maximum at above 600 nm. In this method the glycated protein which is labelled by the first signal forming agent may be any one, or indeed any set, of the blood proteins. By appropriate selection of the proteins under assay an indication may be obtained of the history of the patient's blood glucose control over the short, medium and long (up to 3 months) term.